Product Information
GRISEOFULVIN 125 MG/5 ML SUSP is a generic product labeled by Chartwell RX LLC, priced at $0.2521 per ML under NDC 62135096841. Its NADAC has been published 239 times since Nov 10, 2021.
FDA first approved this application on Mar 2, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
125 mg/5mL
Manufacturer
Chartwell RX LLCNDC
62135096841
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GRISEOFULVINApproval Type
Generic (ANDA)
FDA Application
ANDA065200FDA Approved
3/2/2005
TE Code
AB
On Market Since
3/2/2005
Pharmacological Classes
Price Statistics
The NADAC for GRISEOFULVIN 125 MG/5 ML SUSP has been published 239 times since Nov 10, 2021, and over the history we have for it it has declined 4.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2521 per ML |
|---|---|
| All-time high | $0.4099 (Dec 13, 2023) |
| All-time low | $0.2115 (Nov 17, 2021) |
| 52-week high | $0.2898 |
| 52-week low | $0.2471 |
| Median price | $0.3095 |
| Average price | $0.3231 |
| Largest weekly change | -19.8% (Nov 17, 2021) |
| Weeks tracked | 239 |
| Tracking since | Nov 10, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Griseofulvin (microsize) market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Griseofulvin (microsize) market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tubulin Inhibiting Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GRISEOFULVIN 125 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for GRISEOFULVIN 125 MG/5 ML SUSP, manufactured by Chartwell RX LLC, is $0.2521 per ML (NDC 62135096841), effective Sep 30, 2026.
How has the price of GRISEOFULVIN 125 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for GRISEOFULVIN 125 MG/5 ML SUSP has declined 4.4%. It has been tracked across 239 weekly CMS publications since Nov 10, 2021.
What are the highest and lowest recorded NADAC prices for GRISEOFULVIN 125 MG/5 ML SUSP?
Since Nov 10, 2021, the NADAC for GRISEOFULVIN 125 MG/5 ML SUSP has ranged from a low of $0.2115 (Nov 17, 2021) to a high of $0.4099 (Dec 13, 2023), with a median of $0.3095 per ML.
Are there cheaper alternatives to GRISEOFULVIN 125 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of GRISEOFULVIN 125 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GRISEOFULVIN 125 MG/5 ML SUSP?
GRISEOFULVIN 125 MG/5 ML SUSP (NDC 62135096841) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.